Education
About Us
Working with TipRanks
Follow Us
BioLife Solutions (BLFS)
NASDAQ:BLFS
BLFS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.84 - $29.55
Previous CloseN/A
Volume44.73K
Average Volume (3M)350.35K
Market Cap
$1.22B
Enterprise Value$1.16B
Total Cash (Recent Filing)$95.39M
Total Debt (Recent Filing)$30.17M
Price to Earnings (P/E)―
Beta2.05
Next Earnings
May 08, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding47,000,000
10 Day Avg. Volume308,864
30 Day Avg. Volume350,348
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)14.28
Price to Cash Flow (P/CF)178.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit20.11
Enterprise Value/Ebitda-265.10
Forecast
1Y Price Target
$31.38Price Target Upside20.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
BioLife Solutions News
PremiumCompany Announcements
BioLife Solutions Reports Strong 2024 Financial Growth
PremiumCompany Announcements
BioLife Solutions Inc. Projects Strong 2025 Growth---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBioLife Solutions reported strong financial performance in 4Q24, with total revenue exceeding projections and a net loss lower than expected.
Market PositionThe company's focus on core business and cleaning up non-core assets is expected to enhance its business profile and drive profitability.
Strategic FocusBioLife Solutions has successfully completed divesting non-core product lines to improve gross margin and adjusted EBITDA margin.
Bears Say
Operational ChallengesConcerns about staffing and funding at US regulatory agencies might impact approval timelines for new cell and gene therapies.
Regulatory ConcernsEven if staffing and funding concerns at US regulatory agencies cast a pall over the prospects for approvals for new cell & gene therapies, BioLife’s cell processing products can still grow through the increased use of already existing CGT therapies and the expansion of clinical trial activity.
---
Ownership Overview
21.99% Insiders
24.39% Mutual Funds
0.51% Other Institutional Investors
35.50% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BLFS FAQ
What was BioLife Solutions’s price range in the past 12 months?
BioLife Solutions lowest stock price was $14.84 and its highest was $29.55 in the past 12 months.
What is BioLife Solutions’s market cap?
BioLife Solutions’s market cap is $1.22B.
When is BioLife Solutions’s upcoming earnings report date?
BioLife Solutions’s upcoming earnings report date is May 08, 2025 which is in 38 days.
How were BioLife Solutions’s earnings last quarter?
BioLife Solutions released its earnings results on Mar 03, 2025. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.06 by $0.02.
Is BioLife Solutions overvalued?
According to Wall Street analysts BioLife Solutions’s price is currently Undervalued.
Does BioLife Solutions pay dividends?
BioLife Solutions does not currently pay dividends.
What is BioLife Solutions’s EPS estimate?
BioLife Solutions’s EPS estimate is -0.05.
How many shares outstanding does BioLife Solutions have?
BioLife Solutions has 47,000,000 shares outstanding.
What happened to BioLife Solutions’s price movement after its last earnings report?
BioLife Solutions reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.06. Following the earnings report the stock price went up 2.125%.
Which hedge fund is a major shareholder of BioLife Solutions?
Currently, no hedge funds are holding shares in BLFS
---
BioLife Solutions Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.38 (20.88% Upside)
$31.38 (20.88% Upside)
Blogger Sentiment
Bullish
BLFS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 24.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.7%
Last 30 Days ▼ 13.1%
Last 30 Days ▼ 13.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.94%
12-Months-Change
Fundamentals
Return on Equity
-6.14%
Trailing 12-Months
Asset Growth
-2.03%
Trailing 12-Months
Company Description
BioLife Solutions
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
---
BLFS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for BioLife Solutions reflected a positive outlook with significant achievements in strategic portfolio reshaping, improved financial metrics, and a strong cash position. Despite some declines in specific platform revenues and ongoing operating losses, the company is well-positioned for growth in 2025 with record Cell Processing revenue and a strong growth outlook.Read More>---
BLFS Revenue Breakdown
45.91% Cell processing
36.05% Freezer and thaw
18.04% Biostorage services
---
BLFS Stock 12 Month Forecast
Average Price Target
$31.38
▲(20.88% Upside)
Technical Analysis
Best Analysts Covering BLFS
1 Year
1 Year Success Rate
10/11 ratings generated profit
1 Year Average Return
+40.45%
reiterated a buy rating 27 days ago
Copying Matt Hewitt's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +40.45% per trade.
---